$DNDN Headlines Dendreon jumps on winning European

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
$DNDN Headlines

Dendreon jumps on winning European approval for prostate-cancer treatment 11:31 a.m. Sept. 17, 2013 - Russ Britt
Storm clouds getting darker for troubled Seattle biotech Dendreon 10:49 a.m. Aug. 23, 2013 - Russ Britt
Dendreon shares slump 16% on poor Provenge outlook 8:12 a.m. Aug. 9, 2013 - MarketWatch
In focus: Bears have another chance 8:09 p.m. Aug. 7, 2013 - Lawrence G. McMillan
As cancer drug sales struggle, Dendreon shares plunge 12:14 p.m. May 9, 2013 - Russ Britt
Analyst apologizes to clients for his call on Dendreon, stock climbs 12:00 p.m. March 7, 2013 - blogs.marketwatch.com
Four charts to watch 2:03 p.m. Feb. 7, 2013 - The Trading Deck
Synageva director bought shares for trust 1:41 p.m. Jan. 17, 2013 - Insider Monkey
Friday’s movers; Best Buy has best day in 4 years 4:47 p.m. Jan. 11, 2013 - Sue Chang
Bernstein lifts Dendreon price target to $10 7:34 a.m. Jan. 11, 2013 - Greg Morcroft
Dendreon upgraded to outperform by Bernstein 7:34 a.m. Jan. 11, 2013 - Greg Morcroft
Analyst downgrades rain on Dendreon 2:43 p.m. July 31, 2012 - Val Brickates Kennedy
Dendreon down 21% on earnings, restructuring news 9:27 a.m. July 31, 2012 - Val Brickates Kennedy
Updates, advisories and surprises 7:31 p.m. July 30, 2012 - MarketWatch
Seagate shares drop on earnings, outlook 5:33 p.m. July 30, 2012 - Wallace Witkowski
Dendreon to slash jobs amid tepid earnings 5:12 p.m. July 30, 2012 - Val Brickates Kennedy
Dendreon shares drop 18% after being unhalted 5:10 p.m. July 30, 2012 - Wallace Witkowski
Dendreon to restructure, slash 600 jobs 3:31 p.m. July 30, 2012 - Val Brickates Kennedy
Dendreon shares halted for news pending 3:13 p.m. July 30, 2012 - Laura Mandaro
Savient to slash workforce by 35% 11:08 a.m. July 9, 2012 - MarketWatch.com


Dendreon (DNDN) Highlighted As Today's Perilous Reversal Stock 3:33 p.m. Today - TheStreet.com
Dendreon (DNDN) in Focus: Stock Moves 9.7% Higher - Tale of the Tape 8:30 a.m. Today - Zacks.com
Investments On Biotech's Cutting Edge: Joseph Pantginis 4:41 p.m. Nov. 18, 2013 - Seeking Alpha
The Immunotherapy Company You Never Saw Coming: Advaxis CSO Interview 12:48 p.m. Nov. 17, 2013 - Seeking Alpha
Dendreon Narrows Loss, Provenge Disappoints Again - Analyst Blog 9:50 a.m. Nov. 15, 2013 - Zacks.com
Dendreon: A Classic Plan Of Desperation 2:38 p.m. Nov. 13, 2013 - Seeking Alpha
Dendreon's Earnings Review 10:47 a.m. Nov. 13, 2013 - Seeking Alpha
Dendreon Has Another Disaster Quarter 9:02 a.m. Nov. 13, 2013 - Seeking Alpha
Combination Therapies Hold Key To Future Cancer Treatments 2:32 p.m. Nov. 12, 2013 - Seeking Alpha
Dendreon Corporation CEO Discusses Q3 2013 Results - Earnings Call Transcript 11:59 a.m. Nov. 12, 2013 - Seeking Alpha
Dendreon Restructuring Aims to Thwart Weak Provenge Sales 9:35 a.m. Nov. 12, 2013 - 247WallSt.com
Dendreon Earnings Suck, But Still Send DNDN Stock Higher 3:40 a.m. Nov. 12, 2013 - InvestorPlace.com
Earnings Season Is Not Over: D.R. Horton, Dendreon, Dean Foods And Health Management Associates 10:20 a.m. Nov. 11, 2013 - Seeking Alpha
Is Dendreon A Buy Ahead Of Earnings? 12:45 p.m. Nov. 6, 2013 - Seeking Alpha
December 6th Options Now Available For Dendreon (DNDN) 10:46 a.m. Oct. 31, 2013 - TheStreet.com
The Deal: After String of Miscues, Dendreon Likely on Block 12:59 p.m. Oct. 30, 2013 - TheStreet.com
Biotechnology: Finding The Best And Worst Value In The Industry 10:20 a.m. Oct. 30, 2013 - Seeking Alpha
Is Dendreon up for Sale? - Analyst Blog 5:10 p.m. Oct. 29, 2013 - Zacks.com
Stock To Watch: Dendreon (DNDN) In Perilous Reversal 9:52 a.m. Oct. 29, 2013 - TheStreet.com
Stocks Cautious on Eve of Fed Meeting as Apple Reports 4:38 p.m. Oct. 28, 2013 - TheStreet.com


NanoString Technologies Names David W. Ghesquiere Senior Vice President, Corporate & Business Development 4:05 p.m. Today - BusinessWire
Marketing Authorizations, Financial Results, Public Offering and Leadership Transitions - Research Report on Regeneron, Dendreon, Dyax, Techne, and ICU Medical 8:04 a.m. Nov. 15, 2013 - PR Newswire
StemCells, Inc. Appoints Greg Schiffman as Chief Financial Officer 9:00 a.m. Nov. 14, 2013 - GlobeNewswire
Under AAAResearchReports.com Microscope: Repros Therapeutics Inc., Dendreon Corp., Novartis AG, and Stryker Corp. 8:10 a.m. Nov. 13, 2013 - PR Newswire
ARIA, DNDN, HSOL and OREX added to NASDAQ Active Stock Watch List at EPR 9:29 a.m. Nov. 12, 2013 - ACCESSWIRE
Dendreon Announces Third Quarter 2013 Results 8:00 a.m. Nov. 12, 2013 - BusinessWire
RBCC Explores Promising New Breakthroughs in Regenerative Medicine 6:46 a.m. Nov. 5, 2013 - BusinessWire
SNTA, DNDN, ZGNX and NVGN added to NASDAQ Active Stock Watch List at EPR 8:58 a.m. Oct. 28, 2013 - ACCESSWIRE
Market Briefing: Emerging Growth NASDAQ Stocks in the News 2:22 p.m. Oct. 25, 2013 - PR Newswire
Quarterly Reports, Licensing Agreements, and Clinical Data - Research Report on Theravance, Dendreon, ImmunoGen, Compugen, and Acorda 7:00 a.m. Oct. 22, 2013 - PR Newswire
Early Briefing and Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc. 7:00 a.m. Oct. 22, 2013 - PR Newswire
Mentor Capital Cancer Immunotherapy Index Up 100% in 2013 7:03 a.m. Oct. 16, 2013 - BusinessWire
Dendreon to Host Conference Call on November 12 to Announce Third Quarter Financial Results 3:30 p.m. Oct. 7, 2013 - BusinessWire
Dendreon Corporation Announces Presentation of PROVENGE(R) (sipuleucel-T) Data at the 2013 European Cancer Congress 6:30 a.m. Sept. 27, 2013 - BusinessWire
Pre-Market Review: Dendreon Corp., Stryker Corp., Novartis AG, and Repros Therapeutics Inc. 7:49 a.m. Sept. 25, 2013 - PR Newswire
Dendreon Announces Marketing Authorization for PROVENGE(R) in the European Union 7:30 a.m. Sept. 17, 2013 - BusinessWire
MOLX, MNKD, ISIS and DNDN added to Healthcare Stock Watch List at EPR 8:31 a.m. Sept. 10, 2013 - ACCESSWIRE
Wall Street Fundamentals Releases New In-Depth Stock Reports on DNDN, HALO, MNKD and PDLI 7:30 a.m. Sept. 10, 2013 - ACCESSWIRE
Five Star Equities Issues New Research Reports on ARUN, DNDN, MENT and P 7:41 a.m. Aug. 26, 2013 - ACCESSWIRE
Acquisitions, Successful Clinical Trials, and Financial Results - Research Report on Medtronic, Osiris, Community Health Systems, Dendreon, and Insys Therapeutics 7:00 a.m. Aug. 21, 2013 - PR Newswire

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Top 5 Most Recently Viewed Articles

Arianna Huffington's Journey: Redefining Success Through Wellbeing

Updated Category News Views 309

Arianna Huffington's Experience with Overworking Arianna Huffington is widely recognized for launching The Huffington Post news website in 2005. However, her journey took a significant turn just two years later when she suffered a collapse in her office due to extreme exhaustion and lack of sleep. This pivotal moment compelled Huffington to rethink the culture of...

Continue Reading
Key Insights into Rathbones Group Plc's Position in Learning Tech

Updated Category News Views 66

Understanding Public Opening Position Disclosures In the realm of financial markets, ensuring transparency is crucial. Public opening position disclosures allow market participants to learn about the interests of individuals and entities in significant securities. One such disclosure recently made headlines as Rathbones Group Plc announced its positions in Learning...

Continue Reading
How a Chicken Finger Chain Became a Billion-Dollar Success

Updated Category News Views 345

Todd Graves launched Raising Cane's back in 1996, defying critics who claimed a chicken finger-only menu wouldn’t fly. I mean, come on—banks tossed him aside like last week's stale fries when he tried to secure funding. Imagine that skepticism ringing through Louisiana's south: all they saw was a niche that couldn’t possibly sustain itself. But here’s the kicker:...

Continue Reading
How a $1000 Investment in Orla Mining Could Grow Over Time

Updated Category News Views 126

Exploring the Growth of Orla Mining Investments Orla Mining has shown remarkable performance in the stock market, with an annual increase of 5.29% compared to the wider market over the past five years, delivering an average annual return of 18.92%. Investors are certainly intrigued by the growth factors contributing to a market capitalization of $3.65 billion. Investment...

Continue Reading
Celestica's Upcoming Financial Results and Investor Day Preview

Updated Category News Views 371

Celestica's Announcement for Q3 2025 Financial Results Celestica Inc. (TSX and NYSE: CLS) is gearing up for its third quarter 2025 financial results conference call and an exciting Investor and Analyst Day. The scheduled call will take place on a Tuesday morning soon after the market closes, providing valuable insights to participants. Conference Call Details The...

Continue Reading